The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Biomaterials for mRNA delivery
Open accessAbstract
Messenger RNA (mRNA) has recently emerged with remarkable potential as an effective alternative to DNA-based therapies because of several unique advantages. mRNA does not require nuclear entry for transfection activity and has a negligible chance of integrating into the host genome which excludes the possibility of potentially detrimental genomic alternations. Chemical modification of mRNA has further enhanced its stability and decreased its activation of innate immune responses. Additionally, mRNA has been found to have rapid expression and predictable kinetics. Nevertheless, the ubiquitous application of mRNA remains challenging given its unfavorable attributes, such as large size, negative charge and susceptibility to enzymatic degradation. Further refinement of mRNA delivery modalities is therefore essential for its development as a therapeutic tool. This review provides an exclusive overview of current state-of-the-art biomaterials and nanotechnology platforms for mRNA delivery, and discusses future prospects to bring these exciting technologies into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Different non-viral materials have been designed and optimized for accommodating efficient delivery of diverse RNA molecules as well as multi-component genome editing systems.[22, 34–36]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [34]
In the citing paper
“For many GARDs, the liver is a preferred organ for mRNA-based PRTs because systemically administrated mRNA vehicles are predominantly trapped by the reticuloendothelial system (RES) in the liver.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [34]
In the citing paper
“In addition, the interaction between apolipoprotein E (apoE) and biomaterials such as lipid and lipid derived materials facilitates the accumulation in the liver.[8, 18, 34, 39, 59, 120, 121, 124, 164, 165]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Shaw, G. D., & Kamen, R. (1986) · Cell · doi:10.1016/0092-8674(86)90341-7 · Cited by 3,946
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Design and development of polymers for gene delivery
Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Gold Nanoparticles for Biology and Medicine
Giljohann, D. A., Seferos, D. S., Daniel, W. L., Massich, M. D., Patel, P. C., & Mirkin, C. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904359 · Cited by 2,389
Flagged first, then by citations
Research works printed but not linked: 13
- Quabius, 2015, Nat. Biotechnol., 32, 229
- Stepinski, 2001, RNA, 7, 1486
- Mattozzi, 2014, J. Vis. Exp., 86, e51234
- Dewitte, 2014, J. Controlled Release, 194c, 28, 10.1016/j.jconrel.2014.08.011 · DOI
- Koch, 1973, Curr. Top. Microbiol. Immunol., 62, 89
- Pasquinelli, 1995, RNA, 1, 957
- K. J. Kallen and A.Thess, Therapeutic Advances in Vaccines, 2014, vol. 2, pp. 10–31
- Sebastian, 2012, J. Clin. Oncol., 2012, 30
- Zhang, 2008, ACS Nano, 2, 1696, 10.1021/nn800275r · DOI
- Salvador-Morales, 2009, Biomaterials, 30, 2231, 10.1016/j.biomaterials.2009.01.005 · DOI
- Su, 2011, Mol. Pharm., 8, 774, 10.1021/mp100390w · DOI · Paper page
- Conry, 1995, Cancer Res., 55, 1397
- Anderson, 2003, Hum. Gene Ther., 14, 191, 10.1089/10430340360535751 · DOI · Paper page
Cited by
Sorted by citations
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationIntracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 767
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
Metadata
- Authors
- Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Corresponding author
- Zetter, Bruce R.
- Shi, Jinjun
- Venue
- Biomaterials Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2015
- Volume
- 3
- Issue
- 12
- Pages
- 1519-1533
- ISSN
- 2047-4830 (ISSN-L)
- 2047-4849
- PMC
- PMC4641793
- OpenAlex
- W1945220000
- Cited by
- 176
- References
- 123
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 13 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 27 · 2019: 16 · 2018: 24 · 2017: 13 · 2016: 11
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biomaterials Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (R01 CA37393, R01CA037393, R00CA160350)
- DOD Prostate Cancer Research Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- mRNA delivery, biomaterials, nanotechnology, mRNA therapeutics, mRNA stability, innate immune response, mRNA degradation, nucleic acid delivery systems
- MeSH terms
- Biocompatible Materials, Biological Transport, Genetic Vectors, Humans, RNA, Messenger, Transfection, Gene Transfer Techniques, Nanotechnology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
